Lorcaserin hydrochloride for the treatment of obesity and overweight
Following on from information provided to NICE by the company in October 2009, the appraisal of Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 377
Referral date 01 June 2010
Topic area
  • Endocrine, nutritional and metabolic
  • Public health

Provisional Schedule

Closing date for invited submissions / evidence submission: 15 February 2013
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC

Project Team

Communications manager: Alice Law
Executive Lead: Andrew Dillon
Project manager: Kate Moore
Technical Lead: Grace Jennings

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 October 2022 Following on from information provided to NICE by the company in October 2009, the appraisal of Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
31 October 2022 Discontinued. Following on from information provided to NICE by the company in October 2009, the appraisal of Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
22 May 2013

NICE has been informed by the sponsor, Arena Pharmaceuticals, that they have withdrawn their licensing application for the above indication. The company is currently evaluating the best approach for submitting at a later date. Therefore this topic has now been suspended. We will continue to monitor any development and update you if the situation changes.

03 May 2013

Following an update on the regulatory status of this technology from the manufacturer, the discussion of this appraisal at the Committee meeting on 30 May 2013 has been cancelled.

We will update you with more information in due course.

23 July 2012

Following on from advice received from the manufacturer, this appraisal has now been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early December 2012. The deadline for submissions is expected in approximately mid February 2013.

02 November 2011

Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid October 2012. The deadline for submissions is expected in approximately mid December 2012.


For further information on our processes and methods, please see our CHTE processes and methods manual